Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Blood

• Publication date

  1997-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V89.4.1405PMID 9028964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutations in the Wilms' tumor gene WT1 in leukemias.

  1996cited by this paper
• Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis.

  1996cited by this paper
• Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.

  1996cited by this paper
• Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow.

  1995cited by this paper
• GATA-1 Transactivates the WT1 Hematopoietic Specific Enhancer (*)

  1995cited by this paper
• Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.

  1995cited by this paper
• Characterization of c-kit expression by primitive hematopoietic progenitors in umbilical cord blood.

  1995cited by this paper
• The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.

  1995cited by this paper
• Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells.

  1994cited by this paper
• Synergistic actions of stem cell factor and other burst-promoting activities on proliferation of CD34+ highly purified blood progenitors expressing HLA-DR or different levels of c-kit protein.

  1994cited by this paper
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.

  1994cited by this paper
• Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells.

  1994cited by this paper
• Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia.

  1994cited by this paper
• Phenotype analysis of hematopoietic CD34+ cell populations derived from human umbilical cord blood using flow cytometry and cDNA-polymerase chain reaction.

  1994cited by this paper
• The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesothelioma

  1993cited by this paper
• A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38- progenitor cells in long-term cultures and semisolid assays.

  1993cited by this paper
• Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells.

  1993cited by this paper
• Human interleukin-4 inhibits proliferation of megakaryocyte progenitor cells in culture.

  1993cited by this paper
• WT-1 is required for early kidney development.

  1993cited by this paper
• Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow.

  1993cited by this paper
• Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor.

  1993cited by this paper
• A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38- progenitor cells in long-term cultures and semisolid assays

  1993cited by this paper
• Human interleukin-4 inhibits proliferation of megakaryocyte progenitor cells in culture

  1993cited by this paper
• Further phenotypic characterization and isolation of human hematopoietic progenitor cells using a monoclonal antibody to the c-kit receptor.

  1992cited by this paper
• Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells.

  1992cited by this paper
• Role of the KIT protooncogene in normal and malignant human hematopoiesis.

  1992cited by this paper
• Expression of the Wilms' tumor gene (WT1) in human leukemias.

  1992cited by this paper
• Characterization of primitive hematopoietic cells in normal human peripheral blood.

  1992cited by this paper
• Differentiation and maturation of growth factor expanded human hematopoietic progenitors assessed by multidimensional flow cytometry.

  1992cited by this paper
• Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells.

  1991cited by this paper
• Expression and function of c-kit in hemopoietic progenitor cells

  1991cited by this paper
• Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: functional properties and composite antigenic profile.

  1991cited by this paper
• c-kit expression by CD34+ bone marrow progenitors and inhibition of response to recombinant human interleukin-3 following exposure to c-kit antisense oligonucleotides.

  1991cited by this paper
• Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development

  1991cited by this paper
• Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry.

  1991cited by this paper
• Analysis of CD34-positive hemopoietic progenitor cells from normal human adult peripheral blood: flow-cytometrical studies and in-vitro colony (CFU-GM, BFU-E) assays

  1991cited by this paper
• Blast colony-forming cells and precursors of colony-forming cells detectable in long-term marrow culture express the same phenotype (CD33- CD34+).

  1991cited by this paper
• Colony formation of clone-sorted human hematopoietic progenitors.

  1990cited by this paper
• Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma

  1990cited by this paper
• Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro.

  1989cited by this paper
• Sequential loss of CD34 and class II MHC antigens on purified cord blood hematopoietic progenitors cultured with IL-3: characterization of CD34-, HLA-DR+ cells.

  1989cited by this paper
• Sequential loss of CD34 and class II MHC antigens on purified cord blood hematopoietic progenitors cultured with IL-3: characterization of CD34-, HLA-DR+ cells

  1989cited by this paper
• Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro.

  1988cited by this paper
• The generation of human long-term marrow cultures from marrow depleted of Ia (HLA-DR) positive cells.

  1984cited by this paper
• Continuous human bone marrow culture: Ia antigen characterization of probable pluripotential stem cells.

  1980cited by this paper

• Tuning the sensitivity of mechanosensory receptors through histidine scanning.

  2026cites this paper
• Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer

  2025cites this paper
• Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers

  2025cites this paper
• Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities

  2025cites this paper
• Next-generation cancer vaccines and emerging immunotherapy combinations.

  2024cites this paper
• Adoptive cellular therapy after hematopoietic stem cell transplantation

  2024cites this paper
• High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk

  2023cites this paper
• WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens

  2023cites this paper
• T Cells Expressing a Modified FcγRI Exert Antibody-Dependent Cytotoxicity and Overcome the Limitations of CAR T-cell Therapy against Solid Tumors

  2023cites this paper
• Immunotherapy in leukaemia

  2023cites this paper
• Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia

  2022influential citation
• Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects

  2022cites this paper
• Incidence and Prognostic Impact of WT-1 Gene Exon7 and 9 Mutations in Acute Promyelocytic Leukemia

  2022cites this paper
• A Novel HAGE/WT1-ImmunoBody® Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone

  2021cites this paper
• A Minority of T Cells Recognizing Tumor-Associated Antigens Presented in Self-HLA Can Provoke Anti-Tumor Reactivity.

  2020cites this paper
• T cell optimization for graft-versus-leukemia responses.

  2020cites this paper
• Development of a T‐cell receptor mimic antibody targeting a novel Wilms tumor 1‐derived peptide and analysis of its specificity

  2020cites this paper
• WT1 Expression in Peripheral Blood at Diagnosis and During the Course of Early Consolidation Treatment Correlates With Survival in Patients With Intermediate and Poor-Risk Acute Myeloid Leukemia.

  2020cites this paper
• Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia

  2020cites this paper
• Immune escape and immunotherapy of acute myeloid leukemia.

  2020cites this paper
• c-MYB and DMTF1 in Cancer

  2019cites this paper
• Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia

  2019cites this paper
• The novel thioredoxin reductase inhibitor A-Z2 triggers intrinsic apoptosis and shows efficacy in the treatment of acute myeloid leukemia.

  2019cites this paper
• TCR-based Immunotherapy for Hematologic Malignancies

  2019cites this paper
• Antigen Targets for the Development of Immunotherapies in Leukemia

  2019cites this paper
• T-Cell Receptor–Based Immunotherapy for Hematologic Malignancies

  2019cites this paper
• Développement d’un modèle murin syngénique et immun de leucémie aiguë myéloïde et de maladie résiduelle mesurable surexprimant ou non le gène Wilms Tumor 1

  2018cites this paper
• T Cell Receptor Mimic Antibodies

  2018cites this paper
• Treating hematological malignancies with cell therapy: where are we now?

  2018cites this paper
• Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

  2018cites this paper
• Results of Molecular Monitoring in Posttransplant Period by Means of Series Investigation of WT1 Gene Expression in Patients with Acute Myeloid Leukemia

  2018cites this paper
• Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network

  2018cites this paper
• Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

  2018cites this paper
• Cancer‐related mRNA expression analysis using a novel flow cytometry‐based assay

  2018cites this paper
• Aberrant expression of ETS1 and ETS2 proteins in cancer.

  2018cites this paper
• Wilms’ tumor 1 (WT1) as a prognosis factor in gynecological cancers

  2018cites this paper
• SEROPREVALENCE OF HUMAN T-CELL LYMPHOTROPHIC VIRUS AND ITS ASSOCIATION WITH WILMS TUMOUR ANTIGEN AMONG WOMEN ATTENDING POST-NATAL CLINICS IN ZARIA NIGERIA.

  2018influential citation
• The Roles of WT1 and BASP1 in the Development and Maintenance of the Posterior Taste Field

  2018cites this paper
• Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation.

  2017cites this paper
• A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

  2017cites this paper
• Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21)

  2017cites this paper
• Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients

  2017influential citation
• Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.

  2017cites this paper
• A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

  2017cites this paper
• The CUG-translated WT1, not AUG-WT1, is an oncogene

  2017cites this paper
• A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia

  2017cites this paper
• Longitudinal analyses of leukemia-associated antigen-specific CD8+ T cells in patients after allogeneic stem cell transplantation.

  2016cites this paper
• Significance of Wilms’ tumor gene 1 as a biomarker in acute leukemia and solid tumors

  2016cites this paper
• Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.

  2016cites this paper
• Loss of Dnmt3b accelerates MLL-AF9 leukemia progression

  2016cites this paper
• HIF-2α, acting via miR-191, is involved in angiogenesis and metastasis of arsenite-transformed HBE cells.

  2016cites this paper
• The Genetic Basis of Haematological Cancers: Tosi/The Genetic Basis of Haematological Cancers

  2016cites this paper
• Novel Immunotherapies for Hematological Malignancies.

  2016cites this paper
• Wilms’ tumor 1 gene expression levels in acute promyelocytic leukemia compared to other acute myeloid leukemia subtypes

  2016cites this paper
• Novel Molecular Markers for Breast Cancer

  2016cites this paper
• Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN)

  2016cites this paper
• Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers

  2016cites this paper
• WT1 Gene Overexpression in Oncohematological Disorders: Theoretical and Clinical Aspects (Literature Review)

  2016cites this paper
• Inhibitory effects of crude ethanolic leave extract from Moringa oleifera Lam. on Wilms’ tumor 1 protein expression in K562 leukemic cell line

  2016cites this paper
• WT1 Mutation in Childhood Cancer.

  2016cites this paper
• Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma

  2016cites this paper
• WT1 role in mammary gland and breast cancer biology

  2015cites this paper
• Wilms tumor gene 1 expression as a predictive marker for relapse and survival after hematopoietic stem cell transplantation for myelodysplastic syndromes.

  2015cites this paper
• A multigene array for measurable residual disease detection in AML patients undergoing SCT

  2015cites this paper
• TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.

  2015cites this paper
• Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

  2015cites this paper
• Molecular Monitoring of WT1 Gene Expression Level in Acute Myeloid Leukemias after Allogeneic Hematopoietic Stem Cell Transplantation

  2015cites this paper
• Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high‐risk subgroup using WT1 expression in association with NPM1 and FLT3‐ITD mutations

  2015cites this paper
• Haematological malignancies: at the forefront of immunotherapeutic innovation

  2015cites this paper
• Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer

  2015cites this paper
• A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype

  2015cites this paper
• Randomized Phase II Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy

  2015influential citation
• Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies

  2015influential citation
• Immunotherapy Targeting Leukemia Stem Cells

  2015cites this paper
• Graft-versus-host disease versus graft-versus-leukemia.

  2015cites this paper
• DNA vaccines, electroporation and their applications in cancer treatment

  2015cites this paper
• Human Tumor Antigens and Cancer Immunotherapy

  2015cites this paper
• Wilms' tumor gene 1 in different types of cancer

  2015cites this paper
• Analogue peptides for the immunotherapy of human acute myeloid leukemia

  2015cites this paper
• Effect of crude ethanolic extract of Ratchadat (Brucea amarissima) fruit on cell cytotoxicity and Wilms’ tumor 1 protein expression in K562 leukemic cell line

  2014cites this paper
• Correlation between solid papillary carcinoma and associated invasive carcinoma according to expression of WT1 and several MUCs.

  2014cites this paper
• WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups

  2014cites this paper
• Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.

  2014cites this paper
• Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma

  2014cites this paper
• Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation

  2014cites this paper
• Acute myeloid leukaemia

  2014cites this paper
• Adoptive T-cell therapy for Leukemia

  2014cites this paper
• Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

  2014cites this paper
• The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation‐induced cell death in leukemic T cells

  2014cites this paper
• Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.

  2014cites this paper
• WT1 regulates angiogenesis in Ewing Sarcoma

  2014cites this paper
• Prognostic significance of WT1 expression in soft tissue sarcoma

  2014cites this paper
• Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype

  2014cites this paper
• Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

  2014cites this paper
• Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody–Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds

  2014cites this paper
• Re‐adapting T cells for cancer therapy: from mouse models to clinical trials

  2014cites this paper
• WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy

  2014cites this paper
• lymphocytes specific for WT1 Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T

  2013cites this paper
• MOLECULAR MECHANISMS ASSOCIATED WITH ACUTE MYELOID LEUKEMIA: REVIEW ARTICLE

  2013cites this paper
• Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

  2013cites this paper